Wishing a sincere Shubh Deepavali to all who are celebrating the start of #Diwali, the Festival of Lights. #BelongAtAbbVie [Video description: Imagery showing Diwali celebrations including sparklers, lights and lanterns, and candles.]
AbbVie
Fabricación de productos farmacéuticos
North Chicago, Illinois 1.447.833 seguidores
Sobre nosotros
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. AbbVie employs approximately 26,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter and like us on Facebook.
- Sitio web
-
http://www.abbvie.com
Enlace externo para AbbVie
- Sector
- Fabricación de productos farmacéuticos
- Tamaño de la empresa
- Más de 10.001 empleados
- Sede
- North Chicago, Illinois
- Tipo
- Empresa pública
- Especialidades
- Biopharmaceutical, Biotechnology, Innovation, Research and Development, Manufacturing, Biotherapeutics, Oncology, Immunology, Virology, Neuroscience, Womens Health, Aesthetics y Eye Care
Ubicaciones
Empleados en AbbVie
Actualizaciones
-
NEWS: Today we announced a collaboration and option-to-license agreement with EvolveImmune Therapeutics to develop novel multispecific therapeutic antibodies for solid and hematologic malignancies. Learn more: https://bit.ly/4frlfVv #oncology #cancer [Video description: On-screen text reads, "Oncology News."]
-
"We delivered another quarter of strong commercial execution and significant pipeline progress. Based upon the momentum of AbbVie's business and our confidence in the long-term growth outlook, we are once again raising our full-year guidance and are increasing our quarterly dividend," said Rob Michael, our CEO. Learn more about our Q3 2024 #FinancialResults: https://abbv.ie/1e204b $ABBV #earnings [Image description: Summary of AbbVie's Q3 2024 Financial Results, including Raised 2024 Adjusted Diluted EPS Guidance Range, Quarterly Dividend Growth, Adjusted R&D Investment and Net Revenues by Therapeutic Area.]
-
Today on #WorldPsoriasisDay, we are reminded that psoriatic disease not only impacts the patient, but also their loved ones, including families, partners and caregivers. Through ongoing research and dedication to immune-mediated skin diseases, like psoriasis, we strive to meet patient needs and support the community globally. IFPA's report highlights the full impact of psoriasis: https://bit.ly/4hkWKLr [Video description: Vassilis Stakias, Global TA Lead, Dermatology, Global Medical Affairs, AbbVie, says, “Everyday, we prioritize the needs of the patients living with psoriatic disease, so they can feel free in their own skin. This World Psoriasis Day, we also support and recognize how psoriatic disease can impact those beyond the patient in solidarity with the dermatology community.”]
-
At least 60 million people live with psoriatic disease globally. This #WorldPsoriasisDay, we are raising awareness about how this immune-mediated skin disease can impact both the individual and their surrounding loved ones. As we aim to destigmatize #psoriasis and empower patients, we encourage those impacted to engage in meaningful conversations with their doctors to achieve their long-term goals. Learn more about the full impact of psoriasis: https://bit.ly/3NKjoiT [Video description: Animation of a woman, a family, families depicted above the Earth, two people in a room, a family cleaning a home, a family at the pool and a doctor and patient at a desk. On-screen text reads, “Psoriasis is a condition that affects more than just the skin. It impacts the lives of patients and their families worldwide. 90% of family members report that their quality of life is impacted by their relative’s psoriasis. People with psoriasis often avoid leisure activities, missing out on time with family. Family members of people with psoriasis often do more around the house to lighten the load. Learn more about the full impact of psoriasis."]
-
During this year’s Psych Congress, we’ll be discussing the latest developments in #MajorDepressiveDisorder and in #schizophrenia. Learn more about our neuroscience work: https://bit.ly/3AhXJLK #PsychCongress2024
-
-
NEWS: We continue to strengthen our #neuroscience portfolio and technology platforms with the acquisition of Aliada Therapeutics. This acquisition supports our ongoing commitment to driving innovation in neuroscience and developing novel medicines for patients with debilitating neurological disorders, such as Alzheimer’s disease. Learn more: https://bit.ly/40kHubk [Video description: On-screen text reads, "Neuroscience News."]
-
Scientific progress and discoveries don’t just happen. It requires making big bets across #technology, #science and #medicine to help build a better future. Explore: https://bit.ly/3BVwYxk
-
-
Scientific progress requires bold action. We're pleased to be recognized as a place where #science and #scientists can thrive as one of Science Magazine's 2024 Top Employers. #SCTopEmployers
Congratulations to Abbott, Moderna, Novo Nordisk, GSK, Dr. Reddy's Laboratories, Eli Lilly and Company, Merck KGaA, Darmstadt, Germany, Boehringer Ingelheim, Merck, and AbbVie for making it to the top 20 in the Top Employers' rankings! #SCTopEmployers 👉 View the full article and employers' profiles online: https://lnkd.in/eWry_NbM
-
-
Get to know our 2024 #WorkingParents of the Year, Javier Maldonado and Karin Mountain. Caring, professional and highly involved with their families and communities, Javier and Karin represent the best of our organization. Learn more: https://bit.ly/3UjtT0c
-
Páginas asociadas
Páginas similares
Acciones
ABBV
NYSE
20 minutos de retraso
203,85 US$
2,35 (1,166 %)
- Apertura
- 201,6
- Mínimo
- 201,42
- Máximo
- 207,32
Datos de Refinitiv
Consulta más información enFinanciación
AbbVie
2 rondas en total
Ver más información en Crunchbase
Última ronda
Deuda tras OPV
Enlace externo a Crunchbase para la última ronda de financiación
15.000.000.000,00 US$